These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 8598838

  • 1. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L.
    N Engl J Med; 1996 Apr 18; 334(16):1011-7. PubMed ID: 8598838
    [Abstract] [Full Text] [Related]

  • 2. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M.
    N Engl J Med; 1995 Dec 21; 333(25):1662-9. PubMed ID: 7477218
    [Abstract] [Full Text] [Related]

  • 3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
    N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K.
    Antivir Ther; 1996 Aug 11; 1(3):129-40. PubMed ID: 11322246
    [Abstract] [Full Text] [Related]

  • 5. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Aug 11; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 6. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug 11; 10 Suppl 1():S57. PubMed ID: 8595510
    [Abstract] [Full Text] [Related]

  • 7. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA, Swartz C, Wu AW, Haubrich R, Collier AC.
    Antivir Ther; 1999 Aug 11; 4(1):35-44. PubMed ID: 10682127
    [Abstract] [Full Text] [Related]

  • 8. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M.
    Antivir Ther; 1997 Dec 11; 2(4):229-36. PubMed ID: 11327442
    [Abstract] [Full Text] [Related]

  • 9. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct 01; 12(14):F151-60. PubMed ID: 9792371
    [Abstract] [Full Text] [Related]

  • 10. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
    Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA.
    N Engl J Med; 1997 Sep 11; 337(11):734-9. PubMed ID: 9287228
    [Abstract] [Full Text] [Related]

  • 11. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 11; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 12. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan 11; 11(1):1-4. PubMed ID: 11363225
    [Abstract] [Full Text] [Related]

  • 13. Clinical experience with saquinavir.
    Vella S.
    AIDS; 1995 Dec 11; 9 Suppl 2():S21-S25. PubMed ID: 8775803
    [Abstract] [Full Text] [Related]

  • 14. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA, Moyle G, Stellbrink HJ, Barker C.
    AIDS; 1999 May 07; 13(7):851-8. PubMed ID: 10357386
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.
    Clin Pharmacol Ther; 1999 Jun 07; 65(6):661-71. PubMed ID: 10391672
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
    Sangkitporn S, Shide L, Klinbuayaem V, Leenasirimakul P, Wirayutwatthana NA, Leechanachai P, Dettrairat S, Kunachiwa W, Thamlikitkul V.
    Southeast Asian J Trop Med Public Health; 2005 May 07; 36(3):704-8. PubMed ID: 16124442
    [Abstract] [Full Text] [Related]

  • 17. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 18. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J.
    N Engl J Med; 1993 Jul 29; 329(5):297-303. PubMed ID: 8100611
    [Abstract] [Full Text] [Related]

  • 19. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.
    Antivir Ther; 1997 Jul 29; 2(3):175-83. PubMed ID: 11322272
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H.
    JAMA; 1996 Jul 10; 276(2):118-25. PubMed ID: 8656503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.